Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
Nicox’s NCX 470 Demonstrates Significant Intraocular Pressure Lowering in Dolomites Phase 2 Glaucoma Trial

July 1, 2021

View Press Release Corporate presentation Contact us
Previous